

Claims

1. Use of a compound that is effective as selective opiate receptor modulator for the manufacture of a pharmaceutical for the diagnosis, prophylaxis and/or the treatment of neuropathy, the clinical pictures and symptoms associated therewith, and related disorders.
2. Use according to claim 1, characterized in that said receptor modulator is a receptor agonist.
3. Use according to claim 1 or 2, characterized in that said receptor modulator is peripherally selective to the receptor.
4. Use according to one of the claims 1, 2 or 3, characterized in that said opiate receptor is a kappa-opiate receptor.
5. Use according to one of the preceding claims, characterized in that the compound is selected from group consisting of Alvimopan, Loperamide, Asimadoline, Fedotozine, Pentazocine, U62066E, ICI204448, U-50488H, ADL 10-0101, ADL 10-0116 and ADL 1-0398.
6. Use according to one of the preceding claims, characterized in that the compound that is effective as selective opiate receptor modulator is N-methyl-N-[(1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)ethyl]-2,2-diphenylacetamide, and/or a pharmaceutically acceptable derivative, solvate, salt or stereoisomer thereof, including mixtures thereof in all ratios.
7. Use according to one of the preceding claims, characterized in that the related disorders are selected from the group consisting of post-herpetic neuralgia, vulvodynia, lupus erythematosus and chemotherapy

induced neuropathy.

- 5 8. Use of the compound N-methyl-N-[(1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)ethyl]-2,2-diphenylacetamide, hydrochloride, for the manufacture of a pharmaceutical for the prophylaxis and/or treatment of neuropathy.
- 10 9. Pharmaceutical composition, characterized in that it comprises a pharmaceutically effective amount of one or more compounds effective as selective opiate receptor modulators as defined in one of the claims 1 to 6.
- 15 10. Pharmaceutical composition according to claim 9, characterised in that it contains one or more additional compounds, selected from the group consisting of physiologically acceptable excipients, auxiliaries, adjuvants, carriers and pharmaceutically active ingredients other than the compounds according to one of the claims 1 to 6.
- 20 11. Pharmaceutical composition according to claim 10, characterised in that the pharmaceutically active ingredients other than the compounds according to one of the claims 1 to 6 are selected from anti-diabetics and pharmaceutically active ingredients other than the compounds according to one of the claims 1 to 6 that are useful for the diagnosis, prophylaxis and/or the treatment of neuropathy, the clinical pictures and symptoms associated therewith, and related disorders.
- 25 12. Method for manufacture of a pharmaceutical composition according to one of the claims 9 to 11, characterized in that one or more compounds effective as selective opiate receptor modulator as defined in one of the claims 1 to 6 and optionally one or more additional compounds as defined in claim 10 and/or claim 11 are mixed together and converted
- 30

into a pharmaceutical composition suitable for administration.

13. Kit consisting of separate packs of

- 5 a) a pharmaceutically effective amount of one or more selective
 opiate receptor modulators as defined in one of the claims 1 to 6
 and
- 10 b) a pharmaceutically effective amount of one or more compounds,
 selected from pharmaceutically active ingredients other than the
 compounds according to one of the claims 1 to 6.

15

20

25

30